Optima Health plc
("Optima", the
"Company", and, together with its subsidiaries, the
"Group")
Optima Health Secures First License with the
NHS for its Digital Assessment Routing Tool 'DART'
LONDON,
UK, 11 February 2025, Optima Health (AIM: OPT),
the UK's leading provider of technology enabled corporate health
and wellbeing solutions, today announces it has secured the first
licence contract for its proprietary Digital Assessment Routing
Tool (DART) with Mersey & West Lancashire Teaching Hospitals
NHS Trust.
DART has been commissioned to support the safe
and effective stratification of care for musculoskeletal conditions
following a successful four-month quality improvement study
conducted in collaboration with the Trust. The study demonstrated
positive outcomes across all measures which included patient
safety, pathway efficiency, cost savings and patient and clinician
satisfaction. The success of DART has created significant interest
from other NHS musculoskeletal services, creating a new sales
pipeline for Optima Health including application in the NHS to
reduce patient waiting lists.
DART, Optima's wholly owned tool, is DTAC
(Digital Technology Assessment Criteria) certified, and is listed
on the NHS Innovation Service. It's a digital first point of
contact for patients self-referring into a musculoskeletal pathway,
providing an alternative to clinician-led triage. Taking an average
of eight minutes to complete, patients are assessed and routed to
the correct type of care based on the urgency and complexity of
their symptoms, following the "Getting It Right First Time"
principle shown to improve patient outcomes and service
efficiency.
DART has received significant investment and
development by Optima Health, with validation completed in
association with Queen Mary University of London leading to
published papers in international peer-reviewed
journals1,2,3,4,5.
Jonathan Thomas, CEO of Optima Health,
commented: "We are excited to
announce this first licence today for Optima's proprietary tool,
DART. Whilst the value of this initial licence is not material in
the context of the Group's overall revenue and profits, it aligns
with the Company's growth strategy to expand into adjacent markets.
Following the successful four-month quality
improvement study, we have received
significant interest from other NHS trusts and breaking into this
new market, as planned, will provide a healthy new sales pipeline
for Optima Health."
Enquiries
Optima Health
Jonathan Thomas, CEO
Heidi Giles, CFO
|
+44(0)3300085113
media@OptimaHealth.co.uk
|
Nominated Adviser and Corporate Broker
Panmure Liberum Limited
Emma Earl / Will Goode / Mark
Rogers
Rupert Dearden
|
+44 (0)20 3100 2000
|
UK
Financial PR Adviser
ICR Healthcare
Mary-Jane Elliott / Angela Gray /
Lindsey Neville
|
optimahealth@icrinc.com
|
|
|
About Optima
Health
Optima Health is the UK's leading provider of
occupational health and wellbeing services, directly influencing
and improving people's lives for 25 years. Optima Health's
incredible team of professionals quickly and effectively
encapsulate client's needs, supporting organisations of all shapes
and sizes. Through tailored solutions and innovative systems,
Optima Health offers unparalleled clinical expertise to its
clients. These solutions ensure that processes are simple and allow
its clients to spend more time focusing on their employees driving
a healthy, high-performing workplace. For more information visit
www.optima health.co.uk
References
1. Lowe C, Hanuman Sing
H, Browne M, Alwashmi MF, Marsh W, Morrissey
D
Usability Testing of a Digital
Assessment Routing Tool: Protocol for an Iterative Convergent Mixed
Methods Study
JMIR Res Protoc 2021;10(5):e27205
DOI: 10.2196/27205
PMID: 34003135
2. Lowe C, Browne
M, Marsh W, Morrissey D
Usability Testing of a Digital
Assessment Routing Tool for Musculoskeletal Disorders: Iterative,
Convergent Mixed Methods Study
J Med Internet Res
2022;24(8):e38352 DOI: 10.2196/38352
PMID: 36040787
3. Lowe C, Hanuman Sing H,
Marsh W, Morrissey
D
Validation of a Musculoskeletal Digital Assessment Routing
Tool: Protocol for a Pilot Randomized Crossover Noninferiority
Trial
JMIR Res Protoc 2021;10(12):e31541
URL: https://www.researchprotocols.org/2021/12/e31541
DOI: 10.2196/31541
4. Lowe C, Sephton
R, Marsh W, Morrissey D
Evaluation of a
Musculoskeletal Digital Assessment Routing Tool (DART): Crossover
Noninferiority Randomized Pilot Trial
JMIR Form Res 2024;8:e56715 DOI: 10.2196/56715
PMID: 39078682
PMCID: 11322692
5. Lowe C, Atherton L, Lloyd P,
Waters A, Morrissey D
Improving safety, efficiency, cost, and satisfaction across a
musculoskeletal pathway using the Digital Assessment Routing tool
for triage: a quality improvement
study.
JMIR Preprints 07/10/2024:67269
2024 DOI: https://doi.org/10.2196/preprints.67269